Emapalumab-Izsg
Phase 2Small molecule
Emapalumab-Izsg is one of 11 small molecule programs targeting Chronic Granulomatous Disease. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Chronic Granulomatous Disease
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Busulfex
Akero TherapeuticsPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Campath
GGenzyme, a Sanofi Company
Phase 2
Tociluzumab
RochePhase 2
Xeljanz
PfizerPhase 2
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Emapalumab-Izsg
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
JSP191
JJasper Therapeutics, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Granulomatous Disease1 trial
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05463133·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Emapalumab-Izsg. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details